Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) (DREAM)

MAIN ELIGIBILITY CRITERIA Histologically proven metastatic adenocarcinoma of colon or rectum Documented inoperable disease (i.e., not suitable for complete carcinological surgical resection) Measurable lesion as assessed by CT scan or MRI in at least one dimension (longest diameter to be recorded) ≥ 20 mm with conventional CT scan or ≥ 10 mm with spiral CT scan No previous therapy for metastatic disease No history or evidence upon physical examination of CNS disease (e.g., non-irradiated CNS metastasis, seizure not controlled with standard medical therapy, or history of stroke) unless adequately treated No exclusive bone metastasis ECOG performance status 0-2 WBC ≥ 1,500/mm^3 Platelets ≥ 100,000/mm^3 Hemoglobin > 9 g/dL (may be transfused to maintain or exceed this level) Proteinuria < 2+ by dipstick OR ≤ 1 g of protein on 24-hr urine collection Bilirubin < 1.5 times ULN Alkaline phosphatase < 3 times ULN No peripheral sensory neuropathy Negative pregnancy test Fertile patients must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly, or surgically sterilization) No peripheral neuropathy ≥ grade 1 No clinically significant (i.e. active) cardiovascular disease No evidence of bleeding diathesis or coagulopathy No serious, non-healing wound, ulcer, or bone fracture No significant ophthalmologic abnormality More than 28 days since prior major surgical procedure or open biopsy